Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland.
Graduate School for Health Sciences, University of Bern, Bern, Switzerland.
Int J Public Health. 2023 Aug 17;68:1605561. doi: 10.3389/ijph.2023.1605561. eCollection 2023.
There is little data on SARS-CoV-2 in people with rare chronic diseases. We studied incidence and severity of SARS-CoV-2 and its risk factors in people with primary ciliary dyskinesia (PCD) from May 2020 to May 2022. We used self-reported questionnaire data from the COVID-PCD study at baseline or during weekly follow-ups. We studied factors associated with SARS-CoV-2 and symptoms using Poisson regression. By May 2022, 728 people participated (40% male, median age 27 years; range 0-85). 87 (12%) reported SARS-CoV-2 at baseline or during follow-up and 62 people reported an incident SARS-CoV-2 infection during 716 person-years (incidence rate 9 per 100 person years). The strongest predictors for reporting SARS-CoV-2 were exposure during periods where Delta variant was dominant (IRR 4.52, 95% CI 1.92-10.6) and Omicron variants (IRR 13.3, 95% CI 5.2-33.8). Severity was mild; 12 (14%) were asymptomatic and 75 (86%) had symptoms among whom four were hospitalized. None needed intensive care and nobody died. The COVID-PCD study participants did not have a higher incidence of SARS-CoV-2 infections nor higher risk of severe COVID-19 disease than people from the general population.
关于罕见慢性疾病患者的 SARS-CoV-2 数据较少。我们研究了 2020 年 5 月至 2022 年 5 月期间原发性纤毛运动障碍（PCD）患者 SARS-CoV-2 的发病率和严重程度及其危险因素。我们使用 COVID-PCD 研究的自我报告问卷数据进行基线或每周随访。我们使用泊松回归研究与 SARS-CoV-2 和症状相关的因素。截至 2022 年 5 月，共有 728 人参与（40%为男性，中位年龄 27 岁；范围 0-85 岁）。87 人（12%）在基线或随访期间报告 SARS-CoV-2，62 人在 716 人年期间报告了 SARS-CoV-2 感染（发病率为 9/100 人年）。报告 SARS-CoV-2 的最强预测因素是在 Delta 变异株占主导地位（IRR 4.52，95%CI 1.92-10.6）和 Omicron 变异株（IRR 13.3，95%CI 5.2-33.8）期间的暴露。严重程度较轻；12 人（14%）无症状，75 人（86%）有症状，其中 4 人住院。无人需要重症监护，也无人死亡。COVID-PCD 研究参与者的 SARS-CoV-2 感染发生率或重症 COVID-19 疾病风险并不高于一般人群。
